open access

Vol 8, No 2 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2002-12-10
Get Citation

Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer

Paweł Murawa, Robert Kobylarek, Andrzej Gracz, Julian Malicki, Jerzy Kierzkowski
DOI: 10.1016/S1507-1367(03)70994-8
·
Rep Pract Oncol Radiother 2003;8(2):49-56.

open access

Vol 8, No 2 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2002-12-10

Abstract

Aim

To evaluate the feasibility of treatment method (intraperitoneal administration of radiolabelled monoclonal antibody) for patients with gastric cancer.

Method

A total of 15 eligible patients, with histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction, who had undergone resection to remove the primary tumour mass, were enrolled in the study. Eight patients were treated with the study drug and 7 of patients were enrolled into the standard care control arm.

Materials and Results

Mean blood radioactivity peaked between 36 and 48 hours, with a mean peak value of approximately 15% ID. Data previously reported on intraperitoneal Y-HMFG1 treatment of patients with ovarian cancer show peak values of 25 – 35% ID seen at 48 hour post-injection. The present results require confirmation in a large population of gastric cancer patients, but suggest that the transfer of radioactivity into the blood pool is decreased compared with the ovarian cancer patients.

Conclusions

A HAMA response was detected in all patients after treatment, and there is some suggestion that is follows a bi-phasic pattern. If as hypothesised, a HAMA response provides a boost to the immune system, leading to a potential longer term benefit, then the HAMA response seen in this study following pemtumomab treatment is encouraging.

Abstract

Aim

To evaluate the feasibility of treatment method (intraperitoneal administration of radiolabelled monoclonal antibody) for patients with gastric cancer.

Method

A total of 15 eligible patients, with histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction, who had undergone resection to remove the primary tumour mass, were enrolled in the study. Eight patients were treated with the study drug and 7 of patients were enrolled into the standard care control arm.

Materials and Results

Mean blood radioactivity peaked between 36 and 48 hours, with a mean peak value of approximately 15% ID. Data previously reported on intraperitoneal Y-HMFG1 treatment of patients with ovarian cancer show peak values of 25 – 35% ID seen at 48 hour post-injection. The present results require confirmation in a large population of gastric cancer patients, but suggest that the transfer of radioactivity into the blood pool is decreased compared with the ovarian cancer patients.

Conclusions

A HAMA response was detected in all patients after treatment, and there is some suggestion that is follows a bi-phasic pattern. If as hypothesised, a HAMA response provides a boost to the immune system, leading to a potential longer term benefit, then the HAMA response seen in this study following pemtumomab treatment is encouraging.

Get Citation

Keywords

gastric cancer; intraperitoneal infusion; radiolabelled monoclonal antibody

About this article
Title

Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 8, No 2 (2003)

Pages

49-56

Published online

2003-01-01

DOI

10.1016/S1507-1367(03)70994-8

Bibliographic record

Rep Pract Oncol Radiother 2003;8(2):49-56.

Keywords

gastric cancer
intraperitoneal infusion
radiolabelled monoclonal antibody

Authors

Paweł Murawa
Robert Kobylarek
Andrzej Gracz
Julian Malicki
Jerzy Kierzkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl